MetaCap

Nuvation Bio (NUVB) vs Phibro Animal Health (PAHC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Phibro Animal Health (PAHC) has outperformed Nuvation Bio (NUVB) over the past year, losing 20.0% versus a loss of 45.6%. Over five years, PAHC leads with a +59.4% price change compared with -53.5% for NUVB. Phibro Animal Health is the larger company by market cap ($1.35 billion vs $1.34 billion), about 1.0 times the size, while Nuvation Bio is growing revenue faster (+699.0% vs +17.1%).

Phibro Animal Health pays a dividend yielding 1.44%, while Nuvation Bio does not currently pay one. Phibro Animal Health converts more of its revenue into profit, with a net margin of 6.6% versus -325.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NUVB-45.64%PAHC-20.03%
+48%-1%-50%
Nov 21, 20251 yearNov 20, 2026
NUVB-58.01%PAHC+52.78%
+178%+38%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NUVB versus PAHC key metrics
MetricNUVBPAHC
Share price$3.80$33.29
Market cap$1.34B$1.35B
1-day change-0.26%-2.32%
YTD return-57.59%-10.89%
1-year return-45.64%-20.03%
5-year return-53.49%+59.43%
P/E ratio (TTM)—13.26
Forward P/E—8.58
EPS (TTM)$-0.39$2.51
Dividend yield0.00%1.44%
Annual dividend$0.00$0.48
Revenue (latest FY)$62.90M$1.52B
Revenue growth (YoY)+698.96%+17.12%
Net income (latest FY)$-204.63M$99.72M
Gross margin—33.76%
Operating margin-338.72%12.81%
Net margin-325.31%6.57%
52-week high$9.75$60.08
52-week low$3.71$28.25
Distance from 52-week high-61.03%-44.59%
Analyst consensusstrong_buyhold
Avg. price target upside+227.63%+41.18%
Average volume5.24M228.99K
Shares outstanding352.02M21.11M
Employees3102,605
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PAHC has outperformed NUVB by 25.6 percentage points over the past year.
  • Phibro Animal Health offers a meaningfully higher dividend yield (1.44% vs 0.00%).
  • Phibro Animal Health is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -325.3 cents for Nuvation Bio.
  • Nuvation Bio grew revenue faster in its latest fiscal year (+698.96% vs +17.12%).

About Nuvation Bio

NUVB stock →

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 310 employees

About Phibro Animal Health

PAHC stock →

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees

NUVB vs PAHC FAQ

Which is bigger, Nuvation Bio or Phibro Animal Health?

Phibro Animal Health (PAHC) is larger, with a market capitalization of $1.35B compared with $1.34B for Nuvation Bio (NUVB).

Which stock has performed better over the past year, NUVB or PAHC?

PAHC returned -20.03% over the past 12 months, compared with -45.64% for NUVB (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Nuvation Bio or Phibro Animal Health?

Phibro Animal Health pays a dividend yielding 1.44%, while Nuvation Bio does not currently pay a regular dividend.

Are Nuvation Bio and Phibro Animal Health in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons